List of Excipients in Branded Drug WINRHO SDF

WINRHO SDF Excipient Strategy and Commercial Opportunities

Last updated: August 28, 2026

WINRHO SDF is a plasma-derived Rho(D) immune globulin used for immune thrombocytopenic purpura and prevention of Rh immunization. Its commercial opportunity is less likely to come from a new excipient alone than from an integrated formulation and presentation strategy: improved protein stability, lower administration burden, refrigerated shelf-life, prefilled delivery, and differentiated packaging for hospitals and obstetric clinics.

The product is a biologic, not a conventional small-molecule drug. Its regulatory and intellectual-property profile therefore differs from an ANDA-based generic opportunity. Excipient innovation must support comparability, safety, cold-chain performance, and manufacturing consistency without altering the biological activity or immunoglobulin distribution profile.

What is WINRHO SDF and how is it used?

WINRHO SDF contains human Rho(D) immune globulin, also known as anti-D immune globulin. It is administered intravenously or intramuscularly, depending on the indication, dose, and clinical setting.

Attribute	WINRHO SDF profile
Active ingredient	Human Rho(D) immune globulin
Product class	Plasma-derived immune globulin
Primary indications	Immune thrombocytopenic purpura; prevention of Rh immunization
Routes	Intravenous and intramuscular
Manufacturer and commercial rights	Historically associated with Cangene; U.S. commercial rights have been associated with Saol Therapeutics
Dosage forms	Sterile liquid injection in single-use presentations
Storage	Refrigerated storage under the current U.S. product labeling
Preservatives	Product is marketed as a preservative-free injectable
Regulatory pathway	Biologics license application
Generic pathway	No conventional ANDA substitution pathway

The product’s target markets have different formulation requirements. ITP treatment often involves high-dose intravenous administration in a hospital or infusion setting. Rh prophylaxis is usually administered in obstetric, emergency, or outpatient settings, where ease of handling, compact packaging, and reliable intramuscular delivery have greater commercial value.

The current prescribing information should control the final excipient composition, concentration, container closure, and storage claims for any development or licensing decision. [1]

What excipients are used in WINRHO SDF?

WINRHO SDF uses a protein-stabilizing formulation designed for a liquid immunoglobulin product. Glycine is identified in product information as a formulation component. The product is supplied as a sterile, preservative-free solution, and the formulation is designed to maintain immunoglobulin integrity during refrigerated storage.

The principal excipient strategy is functional rather than decorative:

Excipient or formulation element	Commercial function	Key development issue
Glycine-based stabilization	Supports protein solubility and stability	Must be balanced against aggregation, pH, osmolality, and injection tolerability
Controlled ionic environment	Supports protein conformation and tonicity	Excess ionic strength can increase aggregation or affect viscosity
Low-particulate liquid system	Supports parenteral administration	Requires control of visible and subvisible particles
Preservative-free presentation	Reduces preservative-related tolerability and compatibility concerns	Requires strict single-use container and sterility controls
Solvent-detergent manufacturing controls	Reduces risk from enveloped viral contaminants during processing	Residual-process-agent limits and analytical validation are required
Type I glass or compatible polymer container	Protects product during storage and transport	Adsorption, silicone oil, extractables, and container interaction must be assessed

A potential commercial mistake would be to treat glycine replacement as a stand-alone product differentiator. For a plasma-derived polyclonal immunoglobulin, changing the stabilizer can affect aggregation, fragmentation, charge variants, potency, anti-D activity, viscosity, and immunogenicity. The value of a new excipient would depend on a measurable product advantage, such as longer refrigerated shelf-life, reduced agitation sensitivity, lower viscosity, or improved recovery from a prefilled syringe.

Which excipient strategies could improve WINRHO SDF?

Protein-stability optimization

The first opportunity is to optimize the stabilizer system around the existing liquid presentation. Screening could compare glycine with other parenteral protein stabilizers, including selected amino acids, sugars, polyols, and surfactants. The objective would be to reduce:

• Immunoglobulin aggregation
• Fragment formation
• Surface adsorption
• Turbidity and subvisible particles
• Potency loss after temperature excursions
• Degradation during transport and administration

For a plasma-derived product, the screening program must evaluate the full immunoglobulin population rather than a single monoclonal antibody. Anti-D potency and the distribution of immunoglobulin subclasses are central quality attributes.

Low-temperature and excursion stability

WINRHO SDF is refrigerated. A formulation that tolerates short-term temperature excursions could create a practical advantage in obstetric clinics, emergency departments, wholesalers, and international markets.

Commercially useful targets include:

Target	Potential value
Longer room-temperature excursion window	Lower product loss during shipment and clinical handling
Reduced freeze sensitivity	Fewer rejected units after accidental freezing
Lower agitation sensitivity	Better resilience during parcel and hospital transport
Extended refrigerated shelf-life	Lower inventory write-offs and improved channel economics
Stable prefilled syringe performance	Faster administration and less preparation

A new excipient system would need to support validated excursion claims under ICH stability principles and biologics-specific analytical testing. [2]

Prefilled syringe compatibility

A prefilled syringe is one of the strongest formulation-adjacent opportunities. It could reduce vial preparation, improve dosing consistency, and support use in obstetric clinics and ambulatory settings.

The development program would need to assess:

• Protein adsorption to syringe surfaces
• Silicone oil interaction
• Plunger and stopper extractables
• Needle compatibility
• Break-loose and glide forces
• Dose recovery
• Particulate generation
• Storage orientation
• Shipping vibration
• Human factors and administration time

A prefilled presentation could be protected through device, container-closure, manufacturing, and formulation claims. The commercial protection would likely be more practical than a narrow claim to a conventional stabilizer.

Reduced-volume high-concentration formulation

A concentrated formulation could reduce injection volume for intramuscular use or decrease infusion burden for selected intravenous applications. That opportunity has a direct clinical and commercial rationale, but it also has major technical constraints.

Higher protein concentration can increase:

• Viscosity
• Aggregation
• Injection force
• Local injection pain
• Particulate formation
• Syringe delivery variability

The best opportunity may be a moderate concentration increase paired with a low-friction syringe and a formulation that maintains acceptable viscosity. A high-concentration product would require clinical bridging and a clear administration advantage.

Lyophilized or dual-chamber presentation

A lyophilized WINRHO product could improve ambient stability, but it would add reconstitution steps and operational complexity. That tradeoff is unfavorable for routine Rh prophylaxis unless the presentation enables a meaningful reduction in cold-chain cost.

A dual-chamber syringe or vial could provide improved stability while retaining a liquid administration step. The commercial case would be stronger in markets with weak refrigeration infrastructure than in the U.S., where existing products already use established refrigerated distribution.

What formulations are protected by WINRHO SDF patents?

WINRHO SDF is an older biologic product, and its core composition and manufacturing concepts originated before the current wave of biologic lifecycle patenting. No conventional Orange Book listing should be expected because the product is licensed as a biologic rather than approved through an NDA.

The commercially relevant protection categories are likely to include:

1. Product composition and anti-D immunoglobulin preparation.
2. Plasma fractionation and purification.
3. Viral inactivation or solvent-detergent processing.
4. Stabilized liquid formulations.
5. Container-closure systems.
6. Methods of treating ITP.
7. Methods of preventing Rh immunization.
8. Manufacturing and quality-control processes.

A definitive current patent landscape cannot be inferred from the product label alone. Older composition and use patents may have expired, while later process, formulation, device, or manufacturing patents could have different expiration dates and geographic scope.

The absence of an Orange Book listing does not mean that no patent risk exists. It means that the principal U.S. patent dispute mechanisms differ from those used for small-molecule products.

When does WINRHO SDF lose exclusivity?

WINRHO SDF does not have a single Orange Book patent expiration date that controls generic entry. The product’s effective exclusivity is determined by a combination of biologics licensing, patent rights, manufacturing know-how, plasma supply, regulatory requirements, and clinical substitution practices.

Exclusivity component	WINRHO SDF relevance
New-drug exclusivity	Not the primary framework for this biologic
Biologic reference-product exclusivity	Potentially relevant to a 351(k) pathway, depending on regulatory classification and reference-product history
Orange Book patents	Not the principal listing mechanism
Paragraph IV certification	Not the standard pathway for a biologic
Trade secrets	Important for plasma sourcing, fractionation, viral safety, and batch consistency
Manufacturing capacity	Significant barrier because anti-D immunoglobulin requires qualified human plasma and validated processing
Clinical substitution	Often depends on institutional protocols and physician practice
Product-specific patents	May cover later formulations, devices, or processes rather than the original product

Under the Public Health Service Act, a biosimilar applicant follows the 351(k) pathway. The applicant must demonstrate biosimilarity through analytical, functional, and clinical evidence appropriate to the product. Interchangeability, if sought, is a separate regulatory determination. [3]

Are there Paragraph IV challenges to WINRHO SDF?

No conventional Paragraph IV challenge is expected for WINRHO SDF because Paragraph IV certifications apply to patents listed in the FDA Orange Book for drug products approved under the Federal Food, Drug, and Cosmetic Act.

A competing Rho(D) immune globulin sponsor would more likely pursue one of four routes:

• An independent biologics license application.
• A 351(k) biosimilar application, if the reference-product and regulatory framework support that approach.
• A product based on a different biologic manufacturing or clinical development strategy.
• A litigation strategy involving process, formulation, device, or use patents.

The practical litigation risk is therefore less likely to be an automatic ANDA launch dispute and more likely to involve patent infringement, trade secrets, regulatory exclusivity, manufacturing records, or biosimilarity.

How strong is the WINRHO SDF patent estate?

The core product estate is likely weaker than a modern branded small-molecule estate because the original product has been commercially available for decades. The stronger barriers are operational and regulatory.

Estate component	Relative strategic strength
Original active-product composition	Low to moderate, depending on surviving claims
Original therapeutic use claims	Low if claims are old or clinically broad
Liquid stabilization	Moderate if supported by narrow, validated claims
Prefilled syringe or delivery device	Moderate to high if technically differentiated
Plasma sourcing and fractionation know-how	High as a trade-secret and execution barrier
Viral-safety process	Moderate to high, depending on claim scope
Manufacturing consistency	High practical barrier, even without broad patent coverage
Clinical and hospital adoption	Moderate commercial barrier
Regulatory comparability package	High cost and time barrier for competitors

The most defensible lifecycle strategy is a portfolio combining formulation, container closure, device, process, and analytical-control claims. A single patent covering an excipient concentration would have limited durability if competitors can change the stabilizer or concentration without losing clinical performance.

Which companies compete with WINRHO SDF?

The relevant competitive set includes other anti-D immune globulin products rather than conventional generic drugs.

Product or competitor	Strategic relevance
RhoGAM	Established anti-D immune globulin competitor with broad obstetric recognition
Rhophylac	Anti-D immune globulin used in Rh prophylaxis and related indications
HyperRHO S/D	Competing human Rho(D) immune globulin product
WINRHO SDF	Differentiated by historical use in ITP as well as Rh immunization prevention
Future plasma-derived or recombinant alternatives	Potential long-term supply and manufacturing disruption

The competitive comparison should focus on route of administration, dose volume, indication breadth, supply reliability, storage, syringe format, adverse-event profile, and hospital contracting. A formulation improvement that does not change one of these purchasing criteria is unlikely to command a substantial premium.

What commercial opportunities exist for WINRHO SDF excipients?

Premium prefilled presentation

A ready-to-administer syringe could command value through labor savings and lower preparation error risk. The strongest initial customer segments would be obstetric clinics, emergency departments, ambulatory centers, and hospital pharmacies.

Temperature-excursion platform

A formulation with validated short-term ambient stability could reduce distribution losses and improve access in countries with inconsistent cold-chain infrastructure. This opportunity would require regional regulatory filings and packaging validation.

Lower-volume administration

A lower-volume intramuscular presentation could improve patient acceptance and simplify administration. The commercial benefit would be clearest where dosing is routine and performed outside infusion centers.

International licensing

A formulation or container-closure technology could be licensed to regional plasma-derived product manufacturers. The licensing model could combine an upfront payment, development milestones, supply rights, and royalties on net sales.

Contract manufacturing and fill-finish

WINRHO SDF or a successor product could support a specialized fill-finish partnership focused on low-volume, protein-based sterile injectables. The value lies in validated handling of immunoglobulin products, not only in the excipient itself.

Hospital procurement differentiation

Excipients can support a broader value proposition based on:

• Reduced waste
• Lower preparation time
• Fewer cold-chain excursions
• Improved dose recovery
• Easier inventory management
• More consistent administration

These benefits should be quantified in pharmacoeconomic or hospital-utilization studies. A formulation change without documented workflow savings would face limited procurement leverage.

What FDA regulatory issues apply to a new WINRHO SDF formulation?

A material change to the excipient system would require regulatory assessment because the product is a biologic. The development package would normally address:

• Identity and purity
• Anti-D potency
• Immunoglobulin subclass distribution
• Aggregates and fragments
• Charge variants
• Protein concentration
• Osmolality and pH
• Sterility and endotoxin
• Particulate matter
• Residual solvent-detergent agents
• Container-closure integrity
• Stability and shipping excursions
• Comparability to the licensed product

The FDA may require a supplement to the existing biologics license or a new application, depending on the magnitude of the change. A formulation that alters route, dose volume, administration method, or clinical performance would create greater regulatory burden than a manufacturing change with demonstrated product comparability. [1][3]

Excipient selection also requires attention to parenteral safety, compendial quality, supplier qualification, viral and microbial control, and global acceptability. A novel excipient would create a substantially larger regulatory package than an established injectable excipient with prior biologic use.

What generic entry risks exist for WINRHO SDF?

The near-term risk is more likely to come from competing branded biologics, supply disruptions, and institutional switching than from a conventional generic launch.

Low-risk scenario

A competitor enters with a comparable anti-D product but lacks ITP positioning, prefilled delivery, or reliable supply. WINRHO SDF retains value through indication breadth and established clinical use.

Moderate-risk scenario

A competing product offers lower volume, a prefilled syringe, better availability, or a more attractive contract price. Hospital protocols begin favoring the competitor for Rh prophylaxis.

High-risk scenario

A biosimilar or independently licensed product achieves strong analytical comparability, obtains broad distribution, and offers a materially lower price. The competitor also secures plasma supply and manufacturing capacity, removing the principal operational barriers.

The most important defense is a differentiated presentation supported by validated stability, reliable supply, and a clear economic advantage.

Key Takeaways

• WINRHO SDF is a plasma-derived Rho(D) immune globulin biologic, not a conventional small-molecule drug.
• The core excipient strategy centers on protein stabilization, preservative-free delivery, refrigerated shelf-life, and low particulate burden.
• Glycine-based stabilization is commercially relevant, but changing the stabilizer alone is unlikely to create durable differentiation.
• Prefilled syringes, reduced injection volume, and temperature-excursion stability offer the strongest lifecycle opportunities.
• WINRHO SDF does not follow the standard Orange Book and Paragraph IV framework.
• The main competitive barriers are biologic comparability, plasma sourcing, manufacturing validation, regulatory evidence, and hospital adoption.
• A successful lifecycle program should combine formulation, device, container-closure, manufacturing, and analytical-control claims.
• The highest-value commercial opportunity is a ready-to-administer, stable, low-volume presentation with measurable hospital workflow benefits.

FAQs

Can a new excipient create a new patent estate for WINRHO SDF?

Yes. Protection could cover a defined formulation, excipient combination, concentration range, container system, or stability profile. The claims must provide a technical advantage that is not readily achieved through routine formulation work.

Would a WINRHO SDF prefilled syringe require a new FDA approval?

A significant presentation or device change would likely require a regulatory submission. The pathway would depend on whether the change affects formulation, dose delivery, administration, stability, or product performance.

Is a biosimilar to WINRHO SDF commercially feasible?

Potentially, but anti-D immune globulin is a complex plasma-derived product. A competitor would need to address donor plasma, fractionation, viral safety, potency, product heterogeneity, and clinical or regulatory comparability.

Which excipient opportunity has the fastest commercial path?

An optimization using established injectable excipients and an existing route of administration generally offers a faster path than a novel excipient, lyophilized product, or major concentration change.

Could WINRHO SDF be reformulated for room-temperature storage?

A room-temperature claim could be commercially valuable, but it would require extensive stability, shipping, container-closure, and comparability evidence. A limited temperature-excursion claim may be more achievable than full room-temperature storage.

References

1. U.S. Food and Drug Administration. (n.d.). WINRHO SDF prescribing information. https://www.fda.gov
2. International Council for Harmonisation. (2003). Q1A(R2): Stability testing of new drug substances and products. https://www.ich.org
3. U.S. Food and Drug Administration. (n.d.). Biosimilar and interchangeable biosimilar products. https://www.fda.gov
4. U.S. Food and Drug Administration. (n.d.). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov
5. U.S. Food and Drug Administration. (n.d.). Drug products approved under the Biologics License Application pathway. https://www.fda.gov